Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Mass. Movers

Synta drug picked for breast cancer study

Synta develops small-molecule drugs to treat cancer and inflammatory diseases.

Synta develops small-molecule drugs to treat cancer and inflammatory diseases.

Continue reading below

Synta Pharmaceuticals Corp. surged on news about its lead cancer drug, ganetespib. The Lexington company had no annual revenue and its quarterly net loss widened 34 percent to $24.2 million. But Synta ended the year with $91.5 million in cash to fund fiscal 2014 operations. The bigger news: Synta and QuantumLeap Healthcare Collaborative said ganetespib will be part of the I-SPY 2 breast cancer trial, a midstage study of locally advanced cancer to see if adding ganetespib to chemotherapy enhances treatment.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week